Author

P. Madrid

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:machine learning (classical)· 3 Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Assay:proteomics· 2 Assay:bulk RNA-seq· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

S. Ekins· 5 shared T. R. Lane· 4 shared A. C. Puhl· 2 shared D. H. Foil· 2 shared H. Zhou· 2 shared J. Dyall· 2 shared M. Holbrook· 2 shared A. N. Freiberg· 1 shared

Activity by Year

2020-2020 · peak 5/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersPharmacology & Toxicology

S. Ekins

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Repurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine and Pyronaridine: In vitro Activity Against SARS-CoV-2 and Potential Mechanisms

A. C. Puhl, E. J. Fritch, T. R. Lane, L. V. Tse, B. Yount, C. Q. Sacramento, T. A. Tavella, F. T. M. Costa, S. Weston, J. Logue, M. Frieman, L. Premkumar, K. H. Pearce, B. L. Hurst, C. H. Andrade, , S. Ekins

This study evaluates the in vitro antiviral activity of three Ebola and Marburg virus inhibitors against SARS-CoV-2 and explores their potential mechanisms of action.

bioRxiv · Dec 1, 2020Pharmacology & Toxicology

Machine Learning Models Identify Inhibitors of SARS-CoV-2

V. O. Gawriljuk, P. P. Kyaw Zin, D. H. Foil, J. Bernatchez, S. Beck, N. Beutler, J. Ricketts, L. Yang, T. Rogers, A. C. Puhl, K. M. Zorn, T. R. Lane, A. S. Godoy, G. Olivia, J. L. Siqueira-Neto, , S. Ekins

The paper uses machine learning to predict SARS-CoV-2 inhibitors from FDA-approved compounds, identifying CPI1062 and CPI1155 as potential antiviral drugs.

bioRxiv · Jun 16, 2020Pharmacology & Toxicology

Repurposing Pyramax for the Treatment of Ebola Virus Disease: Additivity of the Lysosomotropic Pyronaridine and Non-Lysosomotropic Artesunate

T. R. Lane, J. Dyall, L. Mercer, C. Goodin, D. H. Foil, H. Zhou, E. Postnikova, J. Y. Liang, M. Holbrook, P. Madrid, S. Ekins

The paper evaluates the antiviral efficacy of Pyramax(R), a malaria treatment, against Ebola virus and finds its components act additively to inhibit infection.

bioRxiv · Apr 25, 2020 · PreprintPharmacology & Toxicology

Pyronaridine Tetraphosphate Efficacy Against Ebola Virus Infection in Guinea Pig

T. R. Lane, C. Massey, J. E. Comer, A. N. Freiberg, H. Zhou, J. Dyall, M. Holbrook, M. Anantpadma, R. A. Davey, P. Madrid, S. Ekins

This paper evaluates pyronaridine tetraphosphate's efficacy against Ebola and Marburg viruses in guinea pigs, showing 40% survival and suggesting its potential for antiviral repurposing.

bioRxiv · Mar 20, 2020Pharmacology & Toxicology

Tilorone: A Broad-Spectrum Antiviral For Emerging Viruses

S. Ekins, P. Madrid

The paper describes the antiviral activity of tilorone against Chikungunya virus and Middle Eastern Respiratory Syndrome Coronavirus in vitro.

bioRxiv · Mar 9, 2020Pharmacology & Toxicology